• Authors: Nickerson, H. D., Colledge, W. H.
  • Year: 2004
  • Journal: Gene Ther 11 1351-7
  • Applications: in vivo / DNA, oligonucleotide / in vivo-jetPEI-Gal


Intraperitoneal injections of 5 to 50 µg or 50 to 200 µg of antisense oligonucleotide complexed to in vivo-jetPEI-Gal at N/P=10 were performed into neonatal or 4 weeks old mice respectively.


Somatic gene repair of disease-causing chromosomal mutations is a novel approach for gene therapy. This method would ensure that the corrected gene is regulated by its endogenous promoter and expressed at physiological levels in the appropriate cell types. A reporter mouse, Gtrosa26(tm1Col), was generated by targeting a mutated LacZ gene to the Rosa26 locus in mouse embryonic stem (ES) cells. The LacZ gene contains a G to A point mutation, resulting in a Glu to Lys amino-acid substitution at position 461, which abrogates enzymatic activity. The gene is expressed in ES cells, primary embryonic fibroblasts, and in all tissues examined in the adult mouse, including the lung, liver, kidney, spleen, heart, brain and smooth muscle. This transgenic mouse will allow testing of gene repair strategies in vivo and identification of which cell types can be successfully targeted by chromosomal gene repair. Although low levels of gene repair were achieved in the ES cells used to generate the Gtrosa26(tm1Col) mouse, preliminary attempts at gene repair in vivo were unsuccessful, thus highlighting the difficulties that will have to be overcome to get this approach to work.